Baritinib inhibits JAK/STAT signal transduction, IFN-γ-induced CXCL10 expression and immune cell chemotactic activity, indicating its effectiveness for the treatment of SS [55,56,57]. This evidence concerns the gene IFNG and synovial sarcoma.